Synaffix B.V. – Trademark Portfolio
Entity Type: 26
Synaffix B.V. holds 8 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 1 (Chemicals) — 7 filings in this category. The portfolio also extends into Class 44 (Medical Services) across 4 Nice Classification classes. Currently, 2 trademarks are registered and 3 are pending. Notable registered marks include TOXSYN and GLYCOCONNECT. The owner is based in AB Oss.
Kloosterstraat 9
AB Oss NL-5349 , NL
Showing of trademarks Trademarks
Trademark Classifications
Synaffix B.V.'s trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Scientific and technological services; industrial analysis and research services
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does Synaffix B.V. have?
Synaffix B.V. has 8 U.S. trademarks filed with the USPTO. Of these, 2 registered, 3 pending.
What trademark classes does Synaffix B.V. file in?
Synaffix B.V. files trademarks across 4 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 44 (Medical Services), Class 42 (Computer & Scientific), Class 5 (Pharmaceuticals). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.
What are Synaffix B.V.'s most well-known trademarks?
Synaffix B.V.'s registered trademark portfolio includes well-known marks such as TOXSYN and GLYCOCONNECT. These are among 2 currently registered trademarks in the portfolio.
What is Synaffix B.V.'s trademark registration success rate?
Synaffix B.V. has a 100% trademark registration rate, with 2 out of 2 resolved applications resulting in successful registration. Currently, 3 applications are pending review.